body { -ms-overflow-style: scrollbar; overflow-y: scroll; overscroll-behavior-y: none; } .errorContainer { background-color: #FFF; color: #0F1419; max-width: 600px; margin: 0 auto; padding: 10%; font-family: Helvetica, sans-serif; font-size: 16px; } .errorButton { margin: 3em 0; } .errorButton a { background: #1DA1F2; border-radius: 2.5em; color: white; padding: 1em 2em; text-decoration: none; } .errorButton a:hover, .errorButton a:focus { background: rgb(26, 145, 218); } .errorFooter { color: #657786; font-size: 80%; line-height: 1.5; padding: 1em 0; } .errorFooter a, .errorFooter a:visited { color: #657786; text-decoration: none; padding-right: 1em; } .errorFooter a:hover, .errorFooter a:active { text-decoration: underline; } #placeholder, #react-root { display: none !important; } body { background-color: #FFF !important; }

JavaScript is not available.

We’ve detected that JavaScript is disabled in this browser. Please enable JavaScript or switch to a supported browser to continue using twitter.com. You can see a list of supported browsers in our Help Center.

Terms of Service Privacy Policy Cookie Policy Imprint Ads info © 2023 X Corp.

Don’t miss what’s happening

People on X are the first to know.

Post

Conversation

EARLの医学ツイート

不正確な臨床検査に関する報告数が増加の一途をたどっていることを受け、米国FDAは今後、実験室で開発された検査（laboratory developed test；LDT）の安全性と有効性を確保するための規制を導入へ 2023年9月29日　米国FDA

Translate post

3:18 AM · Oct 16, 2023

13.9K

Views

2

Bookmarks

2

New to X?

Sign up now to get your own personalized timeline!

Sign up with Apple

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Trends are unavailable.